Considering that cancer cells are characterized by a high protein synthesis rate, part of the efficacy of the Hsp90 inhibitors may depend on their ability to destabilize DYRK3, thereby promoting SG persistence and perturbing translation restoration after stress. This evidence concerns the gene HSP90AB1 and cancer.